Global Intelligence Center

Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.

BioSante´s innovative vaccine adjuvant and delivery system, BioVant, can increase the effectiveness of flu vaccines, including for the new swine flu vaccine. However, these results are based on per-clinical trials and BioSante’s achievements in this area are still on a research and development level.